274 related articles for article (PubMed ID: 8836549)
1. Coadministration of interleukin-6 (IL-6) and soluble IL-6 receptor delays progression of wobbler mouse motor neuron disease.
Ikeda K; Kinoshita M; Tagaya N; Shiojima T; Taga T; Yasukawa K; Suzuki H; Okano A
Brain Res; 1996 Jul; 726(1-2):91-7. PubMed ID: 8836549
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effect of basic fibroblast growth factor on wobbler mouse motor neuron disease.
Ikeda K; Iwasaki Y; Tagaya N; Shiojima T; Kobayashi T; Kinoshita M
Neurol Res; 1995 Dec; 17(6):445-8. PubMed ID: 8622800
[TBL] [Abstract][Full Text] [Related]
3. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.
Jostock T; Müllberg J; Ozbek S; Atreya R; Blinn G; Voltz N; Fischer M; Neurath MF; Rose-John S
Eur J Biochem; 2001 Jan; 268(1):160-7. PubMed ID: 11121117
[TBL] [Abstract][Full Text] [Related]
4. Oral administration of creatine monohydrate retards progression of motor neuron disease in the wobbler mouse.
Ikeda K; Iwasaki Y; Kinoshita M
Amyotroph Lateral Scler Other Motor Neuron Disord; 2000 Jun; 1(3):207-12. PubMed ID: 11464954
[TBL] [Abstract][Full Text] [Related]
5. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.
Tamura T; Udagawa N; Takahashi N; Miyaura C; Tanaka S; Yamada Y; Koishihara Y; Ohsugi Y; Kumaki K; Taga T
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11924-8. PubMed ID: 8265649
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin treatment attenuates motor neuron degeneration in wobbler mice.
Iwamoto K; Yoshii Y; Ikeda K
Amyotroph Lateral Scler; 2009; 10(5-6):405-9. PubMed ID: 19922131
[TBL] [Abstract][Full Text] [Related]
7. T-588, a novel neuroprotective agent, delays progression of neuromuscular dysfunction in wobbler mouse motoneuron disease.
Ikeda K; Iwasaki Y; Kinoshita M; Marubuchi S; Ono S
Brain Res; 2000 Mar; 858(1):84-91. PubMed ID: 10700601
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 receptor antagonists inhibit interleukin-11 biological activity.
Sun RX; Gennaro C; Rocco S; Gu ZJ; Klein B
Eur Cytokine Netw; 1997 Mar; 8(1):51-6. PubMed ID: 9110148
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
Robak T; Gladalska A; Stepień H; Robak E
Mediators Inflamm; 1998; 7(5):347-53. PubMed ID: 9883970
[TBL] [Abstract][Full Text] [Related]
10. Soluble interleukin-6 receptor (sIL-6R) makes IL-6R negative T cell line respond to IL-6; it inhibits TNF production.
Igaz P; Horváth A; Horváth B; Szalai C; Pállinger E; Rajnavölgyi E; Tóth S; Rose-John S; Falus A
Immunol Lett; 2000 Mar; 71(3):143-8. PubMed ID: 10722865
[TBL] [Abstract][Full Text] [Related]
11. Soluble gp130 is up-regulated in the implantation window and shows altered secretion in patients with primary unexplained infertility.
Sherwin JR; Smith SK; Wilson A; Sharkey AM
J Clin Endocrinol Metab; 2002 Aug; 87(8):3953-60. PubMed ID: 12161539
[TBL] [Abstract][Full Text] [Related]
12. Gene expression of receptors for IL-6, LIF, and CNTF in regenerating skeletal muscles.
Kami K; Morikawa Y; Sekimoto M; Senba E
J Histochem Cytochem; 2000 Sep; 48(9):1203-13. PubMed ID: 10950877
[TBL] [Abstract][Full Text] [Related]
13. Activation of gp130 by IL-6/soluble IL-6 receptor induces neuronal differentiation.
März P; Herget T; Lang E; Otten U; Rose-John S
Eur J Neurosci; 1997 Dec; 9(12):2765-73. PubMed ID: 9517481
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation.
Peviani M; Salvaneschi E; Bontempi L; Petese A; Manzo A; Rossi D; Salmona M; Collina S; Bigini P; Curti D
Neurobiol Dis; 2014 Feb; 62():218-32. PubMed ID: 24141020
[TBL] [Abstract][Full Text] [Related]
16. A complex of the soluble interleukin-6 receptor and interleukin-6 is internalized via the signal transducer gp130.
Graeve L; Korolenko TA; Hemmann U; Weiergräber O; Dittrich E; Heinrich PC
FEBS Lett; 1996 Dec; 399(1-2):131-4. PubMed ID: 8980136
[TBL] [Abstract][Full Text] [Related]
17. Gp130 activation by soluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells.
Erices A; Conget P; Rojas C; Minguell JJ
Exp Cell Res; 2002 Oct; 280(1):24-32. PubMed ID: 12372336
[TBL] [Abstract][Full Text] [Related]
18. Genetic transfer of the wobbler gene to a C57BL/6J x NZB hybrid stock: natural history of the motor neuron disease and response to CNTF and BDNF cotreatment.
Ishiyama T; Klinkosz B; Pioro EP; Mitsumoto H
Exp Neurol; 1997 Nov; 148(1):247-55. PubMed ID: 9398466
[TBL] [Abstract][Full Text] [Related]
19. The soluble form of the IL-6 receptor (sIL-6R alpha) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R alpha-induced AIDS-KS cell growth.
Murakami-Mori K; Taga T; Kishimoto T; Nakamura S
Int Immunol; 1996 Apr; 8(4):595-602. PubMed ID: 8722639
[TBL] [Abstract][Full Text] [Related]
20. Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.
Ganapathi MK; Weizer AK; Borsellino S; Bukowski RM; Ganapathi R; Rice T; Casey G; Kawamura K
Cell Growth Differ; 1996 Jul; 7(7):923-9. PubMed ID: 8809410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
